Sultiame

Sultiame

Clinical data
AHFS/Drugs.com	International Drug Names
Pregnancy category	AU: D US: D (Evidence of risk)
Routes of administration	Oral
ATC code	N03AX03 (WHO)
Legal status
Legal status	UK: POM (Prescription only) US: ℞-only
Pharmacokinetic data
Bioavailability	100% (oral)
Protein binding	29%
Metabolism	Hepatic secretion
Elimination half-life	24 hours
Excretion	Fecal (10%) and renal (90%)
Identifiers
IUPAC name 4-(1,1-dioxothiazinan-2-yl)benzenesulfonamide
CAS Number	61-56-3 N
PubChem CID	5356
DrugBank	DB08329 Y
ChemSpider	5163 Y
UNII	I00Q766CZ2
KEGG	D01787 Y
ChEMBL	ChEMBL328560 Y
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C10H14N2O4S2
Molar mass	290.0395 g/mol
3D model (JSmol)	Interactive image
SMILES O=S2(=O)N(c1ccc(cc1)S(=O)(=O)N)CCCC2
InChI InChI=1S/C10H14N2O4S2/c11-18(15,16)10-5-3-9(4-6-10)12-7-1-2-8-17(12,13)14/h3-6H,1-2,7-8H2,(H2,11,15,16) Y Key:HMHVCUVYZFYAJI-UHFFFAOYSA-N Y
NY (what is this?)  (verify)

WikiDoc Resources for Sultiame
Articles
Most recent articles on Sultiame Most cited articles on Sultiame Review articles on Sultiame Articles on Sultiame in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Sultiame Images of Sultiame Photos of Sultiame Podcasts & MP3s on Sultiame Videos on Sultiame
Evidence Based Medicine
Cochrane Collaboration on Sultiame Bandolier on Sultiame TRIP on Sultiame
Clinical Trials
Ongoing Trials on Sultiame at Clinical Trials.gov Trial results on Sultiame Clinical Trials on Sultiame at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Sultiame NICE Guidance on Sultiame NHS PRODIGY Guidance FDA on Sultiame CDC on Sultiame
Books
Books on Sultiame
News
Sultiame in the news Be alerted to news on Sultiame News trends on Sultiame
Commentary
Blogs on Sultiame
Definitions
Definitions of Sultiame
Patient Resources / Community
Patient resources on Sultiame Discussion groups on Sultiame Patient Handouts on Sultiame Directions to Hospitals Treating Sultiame Risk calculators and risk factors for Sultiame
Healthcare Provider Resources
Symptoms of Sultiame Causes & Risk Factors for Sultiame Diagnostic studies for Sultiame Treatment of Sultiame
Continuing Medical Education (CME)
CME Programs on Sultiame
International
Sultiame en Espanol Sultiame en Francais
Business
Sultiame in the Marketplace Patents on Sultiame
Experimental / Informatics
List of terms related to Sultiame

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Sultiame (rINN, also known as sulthiame) is a sulfonamide and inhibitor of the enzyme carbonic anhydrase. It is used as an anticonvulsant.

History

Sultiame was first synthesised in the laboratories of Bayer AG in the mid 1950s and eventually launched as Ospolot in Europe and other markets the early 1960s. It never became a registered drug in the USA. The brand was transferred to Desitin GmbH in 1993 and is sold in several European countries, in Israel, Japan, and Australia.

Sultiame became established as a second-line drug for treatment of partial epilepsy in the 1960s and 1970s and was often used in combination with the established anticonvulsant phenytoin. Temporal lobe seizures appeared particularly responsive to sultiame. Doubts subsequently arose as to whether sultiame has intrinsic anticonvulsant properties. After discovering sultiame's ability to raise the blood levels of phenytoin, it was assumed that sultiame would only act in combination with phenytoin. This finding, together with the equivocal results of a study in the US, resulted in a quick decline of sultiame's use. It was only in 1988, that the German child neurologist Hermann Doose discovered its specific effects in benign focal epilepsies of childhood. Today, sulthiame is the drug of choice for benign focal epilepsies of childhood (such as benign rolandic epilepsy) in the German-speaking countries and Israel. There is renewed interest in sultiame's other potential uses, e.g., in West syndrome and other refractory epilepsies

Indications

Historically, sultiame has been used to treat partial seizures. In Australia, it is currently registered for behavioural disorders associated with epilepsy; hyperkinetic behaviour; temporal lobe epilepsy; myoclonic seizures; grand mal attacks; and Jacksonian seizures. In contrast to other sulfonamide drugs, sultiame is devoid of antibacterial activity.

Adverse effects

The more common adverse effects are ataxia, paraesthesia of face and limbs, hyperpnoea, dyspnoea, and anorexia. Less common adverse effects include giddiness, rash, Stevens–Johnson syndrome, nausea, weight loss, leukopenia, headache, psychic changes, depression, drooling, increased pain, frequency of fits, insomnia, status epilepticus. Disturbances in calcium and vitamin D metabolism have been occasionally reported after long-term use.

Interactions

Sultiame taken together with primidone may lead to severe side-effects, including psychotic reactions. The addition of sulthiame to phenytoin therapy has shown to be followed by a rise in the serum levels of phenytoin. Sultiame may also lead to a rise of phenobarbitone blood levels. Alcohol must not be consumed during treatment.

Overdose

Vomiting, hypotension, headache, vertigo, ataxia, metabolic acidosis with hyperpnoea and catatonic state may occur. There is no specific antidote. It is not known whether dialysis may help in case of overdose.

Synthesis

Sultiame synthesis: B. Helferich and R. Behnisch, Template:US Patent (1959).

p-Aminobenzenesulfonamide can be alkylated by ω-chlorobutylsulfonyl chloride in base via presumed intermediate, which spontaneously cyclizes to give sulthiame.